BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28740407)

  • 21. A Monoclonal Antibody That Discriminates Between SNAP-Tagged and CLIP-Tagged Proteins.
    Bialon M; Grezella C; Friesen L; Sieben T; Pham AT; Fischer R; Barth S; Püttmann C; Stein C
    Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):141-7. PubMed ID: 27187007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.
    Niesen J; Brehm H; Stein C; Berges N; Pardo A; Fischer R; Ten Haaf A; Gattenlöhner S; Tur MK; Barth S
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1049-61. PubMed ID: 25433506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
    J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.
    Serwotka-Suszczak AM; Sochaj-Gregorczyk AM; Pieczykolan J; Krowarsch D; Jelen F; Otlewski J
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
    Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
    MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry.
    VanBrunt MP; Shanebeck K; Caldwell Z; Johnson J; Thompson P; Martin T; Dong H; Li G; Xu H; D'Hooge F; Masterson L; Bariola P; Tiberghien A; Ezeadi E; Williams DG; Hartley JA; Howard PW; Grabstein KH; Bowen MA; Marelli M
    Bioconjug Chem; 2015 Nov; 26(11):2249-60. PubMed ID: 26332743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
    Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
    Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.
    Law CL; Gordon KA; Toki BE; Yamane AK; Hering MA; Cerveny CG; Petroziello JM; Ryan MC; Smith L; Simon R; Sauter G; Oflazoglu E; Doronina SO; Meyer DL; Francisco JA; Carter P; Senter PD; Copland JA; Wood CG; Wahl AF
    Cancer Res; 2006 Feb; 66(4):2328-37. PubMed ID: 16489038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation and evaluation of the PD0721‑DOX antibody‑drug conjugate targeting EGFRvIII to inhibit glioblastoma.
    Hu M; Liu H; Zhang Y; Lu D; Zheng L; Wang Y; Chen S; Liu T
    Exp Ther Med; 2024 Jun; 27(6):254. PubMed ID: 38682116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical Evaluation of
    Hartimath SV; Alizadeh E; Solomon VR; Chekol R; Bernhard W; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
    J Nucl Med; 2019 Aug; 60(8):1103-1110. PubMed ID: 30655327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bispecific anti-mPDGFRβ x cotinine scFv-C
    Kim S; Kim H; Jo DH; Kim JH; Kim SR; Kang D; Hwang D; Chung J
    Methods; 2019 Feb; 154():125-135. PubMed ID: 30292795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-alkylguanine DNA alkyltransferase.
    Kampmeier F; Ribbert M; Nachreiner T; Dembski S; Beaufils F; Brecht A; Barth S
    Bioconjug Chem; 2009 May; 20(5):1010-5. PubMed ID: 19388673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
    Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
    Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases.
    Yap ML; McFadyen JD; Wang X; Ziegler M; Chen YC; Willcox A; Nowell CJ; Scott AM; Sloan EK; Hogarth PM; Pietersz GA; Peter K
    Theranostics; 2019; 9(4):1154-1169. PubMed ID: 30867822
    [No Abstract]   [Full Text] [Related]  

  • 36. Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models.
    Lhospice F; Brégeon D; Belmant C; Dennler P; Chiotellis A; Fischer E; Gauthier L; Boëdec A; Rispaud H; Savard-Chambard S; Represa A; Schneider N; Paturel C; Sapet M; Delcambre C; Ingoure S; Viaud N; Bonnafous C; Schibli R; Romagné F
    Mol Pharm; 2015 Jun; 12(6):1863-71. PubMed ID: 25625323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment-Drug Conjugates (FDCs).
    Jolivet L; Ait Mohamed Amar I; Horiot C; Boursin F; Colas C; Letast S; Denevault-Sabourin C; Allard-Vannier E; Joubert N; Aubrey N
    Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 35893780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.
    Wang X; Campoli M; Ko E; Luo W; Ferrone S
    J Immunol Methods; 2004 Nov; 294(1-2):23-35. PubMed ID: 15604013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR; Hell T; Merkel AS; Grawunder U
    PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.